Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Primary Purpose
Angioneurotic Edema
Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
HOE-140
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Angioneurotic Edema focused on measuring ACE Inhibitor, Angioedema, Bradykinin, Swelling
Eligibility Criteria
Inclusion Criteria:
- Ambulatory
- ACE inhibitor-associated angioedema, as defined as swelling of the lips, pharynx, or face while taking an ACE inhibitor, no history of angioedema while not taking an ACE inhibitor, and no evidence of abnormal C1 inhibitor concentration or abnormal complement levels. People with possible cases of ACE inhibitor-associated bowel edema will not be enrolled.
- If female, must be postmenopausal for at least 1 year prior to study entry, undergone surgical sterilization, or willing to use an effective form of birth control and take a pregnancy test daily for the duration of the study
Exclusion Criteria:
- Pregnant or breastfeeding
- Started taking birth control pills in the 6 months prior to study entry
Sites / Locations
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
HOE-140
Placebo
Arm Description
Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
Administration of placebo at time 0 and 6 hours
Outcomes
Primary Outcome Measures
Time to resolution of angioedema, as defined as the time interval between when the participant first noted the onset of symptoms and when there is no objective evidence of angioedema by physical examination
Secondary Outcome Measures
Length of hospital stay, admission to the intensive care unit, requirement for intubation, duration of intubation, use of steroids, use of histamine receptor type 1 (H1) and H2 blockers, use of epinephrine, and blood pressure levels
Full Information
NCT ID
NCT00517582
First Posted
August 15, 2007
Last Updated
December 16, 2015
Sponsor
Vanderbilt University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00517582
Brief Title
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Official Title
Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Terminated
Why Stopped
This study was stopped to allow initiation of a mult-center study
Study Start Date
September 2007 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.
Detailed Description
People who take ACE inhibitors may develop angioedema, a condition that causes itchy and painful swelling beneath the skin around the eyes, lips, tongue, throat, hands, or feet. In severe cases, the throat may swell, obstructing the airway and leading to breathing difficulty. ACE inhibitors prevent the breakdown of a natural chemical in the body called bradykinin. Increased levels of bradykinin, which can cause swelling, may contribute to the development of angioedema. Blocking bradykinin receptor cells prevents bradykinin from initiating swelling and may lead to a possible decrease in angioedema symptoms. The purpose of this study is to evaluate the effectiveness of HOE-140, a bradykinin receptor blocker, at reducing symptoms in people with ACE inhibitor-associated angioedema.
This study will enroll people admitted to the emergency room or hospital who have a severe case of ACE inhibitor-associated angioedema. Participants will be randomly assigned to receive an injection of either HOE-140 or placebo. Initially, participants will undergo an electrocardiogram to measure the electrical activity of the heart. Then blood pressure measurements, blood collection, a physical exam to determine the extent and duration of swelling, and photographs of the swelling will occur at 2, 4, 8, 16, and 24 hours following the start of treatment. Questionnaires will be completed by study staff and participants to assess changes in angioedema symptoms and the extent of swelling. Participants will remain in the hospital for 24 to 48 hours, depending on the severity of their symptoms. Blood will be collected at a follow-up visit that will occur 7 days after the resolution of angioedema symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Angioneurotic Edema
Keywords
ACE Inhibitor, Angioedema, Bradykinin, Swelling
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HOE-140
Arm Type
Experimental
Arm Description
Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Administration of placebo at time 0 and 6 hours
Intervention Type
Drug
Intervention Name(s)
HOE-140
Other Intervention Name(s)
icatibant
Intervention Description
Subcutaneous at time 0 and 6 hours
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Subcutaneous at time 0 and 6 hours
Primary Outcome Measure Information:
Title
Time to resolution of angioedema, as defined as the time interval between when the participant first noted the onset of symptoms and when there is no objective evidence of angioedema by physical examination
Time Frame
Measured at follow-up visit 7 days following resolution of angioedema
Secondary Outcome Measure Information:
Title
Length of hospital stay, admission to the intensive care unit, requirement for intubation, duration of intubation, use of steroids, use of histamine receptor type 1 (H1) and H2 blockers, use of epinephrine, and blood pressure levels
Time Frame
Measured at follow-up visit 7 days following resolution of angioedema
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ambulatory
ACE inhibitor-associated angioedema, as defined as swelling of the lips, pharynx, or face while taking an ACE inhibitor, no history of angioedema while not taking an ACE inhibitor, and no evidence of abnormal C1 inhibitor concentration or abnormal complement levels. People with possible cases of ACE inhibitor-associated bowel edema will not be enrolled.
If female, must be postmenopausal for at least 1 year prior to study entry, undergone surgical sterilization, or willing to use an effective form of birth control and take a pregnancy test daily for the duration of the study
Exclusion Criteria:
Pregnant or breastfeeding
Started taking birth control pills in the 6 months prior to study entry
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nancy J. Brown, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37205
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
We'll reach out to this number within 24 hrs